Sign Up to like & get
recommendations!
0
Published in 2021 at "Cancer"
DOI: 10.1002/cncr.33745
Abstract: SF3B1 mutations (SF3B1mut) in myelodysplastic syndromes (MDS) frequently involve codon K700E and have a favorable prognosis. The prognostic effect of non‐K700E SF3B1mut is uncertain.
read more here.
Keywords:
myelodysplastic syndromes;
mutation involving;
sf3b1 mutation;
independently predicts ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2024 at "Leukemia"
DOI: 10.1038/s41375-024-02262-2
Abstract: We investigated data from 180 consecutive patients with myelodysplastic/myeloproliferative neoplasms with SF3B1 mutation and thrombocytosis (MDS/MPN-SF3B1-T) who were diagnosed according to the 2022 World Health Organization (WHO) classification of myeloid neoplasms to identify covariates associated…
read more here.
Keywords:
patients myelodysplastic;
myeloproliferative neoplasms;
sf3b1 mutation;
mutation ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2025 at "American Journal of Clinical Pathology"
DOI: 10.1093/ajcp/aqaf121.231
Abstract: SF3B1 mutations are associated with several hematologic malignancies, including chronic lymphocytic leukemia (CLL) and myelodysplastic/myeloproliferative neoplasms with SF3B1 mutation and thrombocytosis (MDS/MPN-SF3B1-T). CLL cases with SF3B1 mutations often show 11q deletions, while MDS/MPN-SF3B1-T is typically…
read more here.
Keywords:
cll;
sf3b1;
mds mpn;
sf3b1 mutation ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2024 at "Blood"
DOI: 10.1182/blood-2024-204428
Abstract: Myelodysplastic syndromes (MDS) are myeloid malignancies derived from hematopoietic stem progenitor cells (HSPCs), characterized by cytopenia, dysplastic and ineffective hematopoiesis and a high risk of developing acute myeloid leukemia. SF3B1 is the most frequently mutated…
read more here.
Keywords:
sf3b1 k700e;
sf3b1;
mds;
translation ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2022 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2022.905490
Abstract: The outcomes of myelodysplastic syndrome (MDS) patients with SF3B1 mutation, despite identified as a favorable prognostic biomarker, are variable. To comprehend the heterogeneity in clinical characteristics and outcomes, we reviewed 140 MDS patients with SF3B1…
read more here.
Keywords:
prognostic scoring;
sf3b1 mutation;
model;
patients sf3b1 ... See more keywords